Scinai Immunotherapeutics Ltd.SCNI
Price (close)
$1.86
Market cap
—
P/E
—
Revenue (FY)
$1.3M
Net income
-$8.3M
Dividend yield
—
1-year total return
-86.1%
Net margin
-633.6%
Revenue growth
99.2%
Debt / equity
—
What Scinai Immunotherapeutics Ltd. does.
company with two complementary business units: (i) Scinai R&D, focused on the development of innovative therapeutics in inflammation
and immunology, and (ii) our contract development and manufacturing organization (CDMO) business, which operates through our subsidiary,
● PC111 Program – In 2025, we entered into an option agreement, as amended on September 11, 2025 and February 28, 2026, to acquire
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $658,000 | $1.3M |
| Net income | -$1.4M | -$8.2M | -$5.8M | -$6.5M | $4.8M | -$8.3M |
| Free cash flow | -$24.5M | -$7.6M | -$8.1M | -$10.0M | -$6.3M | -$6.1M |
More on SCNI.
- Scinai Immunotherapeutics Ltd. summary
- Scinai Immunotherapeutics Ltd. financial statements
- Scinai Immunotherapeutics Ltd. key metrics
- Scinai Immunotherapeutics Ltd. health scores and style box
- Scinai Immunotherapeutics Ltd. earnings
- Scinai Immunotherapeutics Ltd. dividends
- Scinai Immunotherapeutics Ltd. valuation
- Scinai Immunotherapeutics Ltd. ownership and insiders
- Scinai Immunotherapeutics Ltd. peers
Figures from Scinai Immunotherapeutics Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.